麦澜德（688273）：2025Q3收入平稳增长，利润端表现亮眼

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that will outperform the market benchmark by more than 15% over the next 6-12 months [7]. Core Insights - The company reported a stable revenue growth of 4.01% year-on-year for the first three quarters of 2025, achieving a total revenue of 344 million yuan. The net profit attributable to the parent company was approximately 96 million yuan, showing a slight decrease of 0.07% year-on-year. In Q3 2025, the company generated a revenue of 103 million yuan, a year-on-year increase of 0.42%, while the net profit attributable to the parent company rose by 36.71% to 32 million yuan, primarily due to increased financial subsidies [5][6]. - The company is focusing on high-potential business areas such as brain-computer interfaces, with several key projects underway, including a national key research plan and various provincial initiatives aimed at developing advanced rehabilitation technologies [6]. Financial Performance Summary - For the fiscal year 2025, the company is projected to achieve revenues of 500 million yuan, with a year-on-year growth rate of 17.8%. The net profit attributable to the parent company is expected to be 117 million yuan, reflecting a growth of 15.0%. The earnings per share (EPS) for 2025 is estimated at 1.17 yuan, with a price-to-earnings (P/E) ratio of 34x [11][7]. - The financial forecasts for 2026 and 2027 indicate continued growth, with revenues expected to reach 613 million yuan and 748 million yuan, respectively, and net profits of 164 million yuan and 203 million yuan, with corresponding growth rates of 40.7% and 23.7% [11][7].